Keyphrases
Radiotherapy
100%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
100%
Cancer Chemotherapy
100%
Oral Cavity Cancer
100%
Confidence Interval
57%
Chemotherapy
57%
Hazard Ratio
57%
Overall Survival
42%
Concurrent Chemoradiotherapy
42%
Cochrane Database of Systematic Reviews
28%
Absence of Evidence
28%
Cochrane Review
28%
Oral Cancer
28%
Improved Survival
28%
Risk of Bias
28%
Radiotherapy Alone
28%
Unresectable Tumor
28%
Alternating Chemoradiotherapy
28%
Induction Chemotherapy
28%
Delayed Diagnosis
14%
Oral Health
14%
Sensitivity Analysis
14%
Primary Tumor
14%
Chemotherapy Treatment
14%
Surgery Treatment
14%
New Evidence
14%
Quality of Life
14%
Inclusion Criteria
14%
MEDLINE
14%
Embase
14%
Review Authors
14%
Low Risk
14%
Chemotherapy Regimen
14%
Disease-free Survival
14%
Head-and-neck Cancer
14%
Recurrent Disease
14%
Issue 4
14%
Oral Cavity
14%
Cochrane
14%
Health Groups
14%
Radiotherapy Treatment
14%
Progression-free Survival
14%
Adjuvant Chemotherapy
14%
AMED
14%
Oropharynx
14%
Timing of Surgery
14%
Total Mortality
14%
Combined Regimen
14%
Locoregional Control
14%
Chemoradiation
14%
Relative Timing
14%
Locoregional Treatment
14%
New Combination
14%
Route of Administration
14%
Timing of Radiotherapy
14%
Adjuvant Chemoradiotherapy
14%
Administration Time
14%
Chemotherapy Duration
14%
Chemotherapy Agents
14%
Medicine and Dentistry
Oral Cavity
100%
Chemotherapy of Oropharynx Cancer
100%
Radiation Therapy
100%
Hazard Ratio
40%
Chemoradiotherapy
40%
Cancer
30%
Overall Survival
30%
Oral Cancer
30%
Neoplasm
20%
Systematic Review
20%
Induction Chemotherapy
20%
Recurrent Disease
10%
Disease Free Survival
10%
Side Effect
10%
Quality of Life
10%
Primary Tumor
10%
Group Trial
10%
Progression Free Survival
10%
Oropharynx
10%
Chemotherapy Agent
10%
Head and Neck Cancer
10%
Adjuvant Chemotherapy
10%
Adjuvant Chemoradiotherapy
10%
Oropharynx Carcinoma
10%
Chemotherapy
10%
Diseases
10%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Chemotherapy of Oropharynx Cancer
100%
Chemoradiation Therapy
55%
Overall Survival
33%
Mouth Cancer
33%
Neoplasm
22%
Recurrent Disease
11%
Side Effect
11%
Head and Neck Cancer
11%
Primary Tumor
11%
Group Trial
11%
Progression Free Survival
11%
Oropharynx Cancer
11%
Disease Free Survival
11%
Chemotherapy Agent
11%
Oropharynx Carcinoma
11%
Diseases
11%